Top San Francisco Bay Area, CA Pharmaceutical Companies (65)

GoodRx is America’s healthcare marketplace. Each month, millions of people visit goodrx.com to find reliable health information and discounts for their healthcare — and we’ve helped people save $35 billion since 2011. We provide prescription discounts that are accepted at more than 70,000 pharmacies in the U.S., as well as telehealth services including doctor visits and lab tests. Our goal is...

MEV delivers software solutions to make businesses move faster and adapt to the changing world earlier than competitors. We helped clients from various industries and scales - HealthTech, FinTech, EdTech, Startups, Fortune 500 companies, etc. Our projects include distributed IoT platforms, mobile applications, Client-Server Web Apps, Big Data Analytics systems, AI-based solutions, etc.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive...

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's...

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products. If you are interested in joining a highly innovative and...

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation. The company spans across the globe and maintains offices, R&D centers, and production bases in 12 different cities within the United States, Switzerland, England, Germany, and China. ACROBiosystems...

Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments...

Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the...

Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety...

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach...

SmithRx is committed to providing a straightforward approach to reducing drug costs and improving health outcomes. We understand that reducing pharmacy costs is top of mind for us all. We utilize cloud technologies to deliver the most streamlined and cost-effective PBM solution: one that is modularized and can be tailored to meet individual needs. Our compelling value proposition can be summarized...

At Mendel.ai, our mission is to use our novel AI aided by clinical experts to streamline global oncology research by organizing real world data and automating clinical trials. We build software to solve problems at each stage of the clinical trial process, from feasibility to post-trial pharmacovigilance. We strive for excellency, to be authentic and original, and to make a...

Biocytogen provides integrated solutions for next-generation antibody drug development to the global biomedical communities. Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery and validation, including animal model generation, therapeutic antibody discovery (via RenMab™ mice), and in vivo/in vitro preclinical validation studies. Biocytogen collaborates with more than...

RemeGen is a global biopharmaceutical company, focusing on the discovery, development and commercialization of novel biologics for the treatment of autoimmune, oncology and ophthalmic diseases with significant unmet medical needs. RemeGen Biosciences, a wholly owned subsidiary of RemeGen, is based in South San Francisco, California, the birthplace of biotechnology and in Maryland. Our vision is to create the first-in-class and/or...

Earli mission is to make cancer a benign experience. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology *forces* cancer cells to make a synthetic, non-human biomarker using gene therapy approaches. It's called a Synthetic Biopsy. It can then localize the cancer in a PET scanner. Earli has been funded by...

Develop Health, co-founded by Mel van Londen and Ben Easton, is dedicated to transforming the medication prior authorization process. Their product reduces form completion time by over 80% and increases approval rates. With over 10 years of experience in healthcare, the founding team has impacted 200k+ patients and 6k+ providers, holding notable roles at Canvas Medical, IDEO, and Rupa Health.

Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes which enable real time, molecular-resolution measurements of protein movement in living cells. By directly measuring...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and...